866-997-4948(US-Canada Toll Free)

Irritable Bowel Syndrome - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 54 Pages


GlobalData, the industry analysis specialist, has released its new report, “Irritaable Bowel Syndrome (IBS) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global IBS market. The report identifies the key trends shaping and driving the global IBS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global IBS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData’s analysis suggests that the global IBS market was worth $1.7 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% for the next seven years, to reach $2.72 billion by 2017. The high projected growth rate is primarily attributable to a strong pipeline. Increases in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the IBS market 

Scope 

The report provides information on the key drivers and challenges of the IBS market. Its scope includes:

  • Annualized global IBS market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Serotonin receptor targets, Guanylate cyclase type C receptor agonist, NK receptor targets, CRF1 receptor agonist.
  • Analysis of the current and future competition in the global IBS market. Key market players covered are Ironwood Pharmaceuticals and Forest Laboratories, Tioga Pharmaceuticals, Procter & Gamble (P&G), Lexicon Pharmaceuticals, Salix Pharmaceuticals and Astellas Pharma.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the IBS therapeutics market
Reasons to buy 

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global IBS market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global IBS market landscape? - Identify, understand and capitalize
Table of Contents

1 Table of Contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Irritable Bowel Syndrome Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Irritable Bowel Syndrome: Market Characterization 7
3.1 Irritable Bowel Syndrome Market Size 7
3.2 Irritable Bowel Syndrome Market Forecast and CAGR 7
3.3 Drivers and Barriers for the Irritable Bowel Syndrome Market 8
3.3.1 Drivers 8
3.3.2 Restraints 9
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 11

4 Irritable Bowel Syndrome Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.2.1 Lotronex (Alosetron) 13
4.2.2 Amitiza (Lubiprostone) 15
4.2.3 Colpermin (Peppermint Oil) 17
4.2.4 Bentyl (Dicyclomine hydrochloride) 18
4.3 Key Takeaway 20

5 Irritable Bowel Syndrome Market: Pipeline Assessment 21

5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytical Framework 21
5.3 Irritable Bowel Syndrome Promising Drugs under Clinical Development 23
5.4 Drugs under Clinical Development 24
5.4.1 Linaclotide (Linaclotide Acetate) 24
5.4.2 Asimadoline 25
5.4.3 Xifaxan (Rifaximin) 26
5.4.4 LX-1031 27
5.4.5 YM060 (Ramosetron hydrochloride) 28
5.5 Irritable Bowel Syndrome Market Clinical Pipeline by Mechanism of Action 30
5.6 Irritable Bowel Syndrome Pipeline Pipeline by Clinical Phases of Development 31
5.6.1 Irritable Bowel Syndrome Market Phase III Clinical Pipeline 31
5.6.2 Irritable Bowel Syndrome Market Phase II Clinical Pipeline 32
5.6.3 Irritable Bowel Syndrome Market Phase I Clinical Pipeline 33
5.6.4 Irritable Bowel Syndrome Market Preclinical Pipeline 33
5.6.5 Irritable Bowel Syndrome Market Discovery 33
5.6.6 Irritable Bowel Syndrome Market Status Unknown 33
5.7 Discontinued / Suspended Drugs for Irritable Bowel Syndrome 34
5.8 Key Takeaway 34

6 Irritable Bowel Syndrome Market: Implications for Future Market Competition 35

7 Irritable Bowel Syndrome Market: Future Players in the Irritable Bowel Syndrome Market 37

7.1 Introduction 37
7.2 Ironwood Pharmaceuticals and Forest Laboratories 37
7.2.1 Company Overview 37
7.2.2 IBS pipeline portfolio 38
7.3 Tioga Pharmaceuticals 40
7.3.1 Company Overview 40
7.3.2 IBS Pipeline Portfolio 40
7.4 Alimentary Health Ltd and P&G 41
7.4.1 Company Overview 41
7.4.2 IBS Pipeline Portfolio 41
7.4.3 Bifantis (Bifidobacterium infantis 35624) 42
7.5 Lexicon 43
7.5.1 Company Overview 43
7.5.2 IBS pipeline portfolio 43
7.5.3 LX-1031 43
7.6 Salix Pharmaceuticals 44
7.6.1 Overview 44
7.6.2 IBS pipeline portfolio 44
7.6.3 Xifaxan (Rifaximin) 44
7.7 Astellas Pharma 45
7.7.1 Overview 45
7.7.2 IBS pipeline portfolio 46

8 IBS Market: Appendix 48
8.1 Definitions 48
8.2 Abbreviations 48
8.3 Research Methodology 49
8.3.1 Coverage 49
8.3.2 Secondary Research 49
8.3.3 Forecasting 49
8.3.4 Primary Research 53
8.3.5 Expert Panels 53
8.4 Contact Us 53
8.5 Disclaimer 53
8.6 Sources 54

List of Table


Table 1: Global IBS Market, Revenues ($bn), 2001-2009 7
Table 2: Global IBS Market, Revenues ($bn), 2009-2017 8
Table 3: Five Efficacy Studies in Women 14
Table 4: Major Marketed Products in the IBS Market, 2010 19
Table 5 : IBS Most Promising Drugs Under Clinical Development, 2010 23
Table 6: IBS Market Phase III Clinical Pipeline, 2010 31
Table 7: IBS Market Phase II Clinical Pipeline, 2010 32
Table 8: IBS Market Phase I Clinical Pipeline, 2010 33
Table 9: IBS Market Preclinical Clinical Pipeline, 2010 33
Table 10: IBS Market Discovery Clinical Pipeline, 2010 33
Table 11: IBS Market Status Unknown Clinical Pipeline, 2010 33
Table 12: Discontinued/Suspended Drugs for IBS, 2010 34
Table 13: Ironwood Pharmaceuticals IBS pipeline products, 2010 38
Table 14: Tioga Pharmaceuticals IBS pipeline products, 2010 40
Table 15: Alimentary Health Ltd and P&G IBS pipeline products, 2010 41
Table 16: Lexicon IBS pipeline portfolio, 2010 43
Table 17: Salix Pharmaceuticals IBS pipeline portfolio, 2010 44
Table 18: Astellas Pharma IBS Pipeline Portfolio, 2010 46

List of Chart


Figure 1: Global IBS Market, Revenues ($bn), 2001-2009 7
Figure 2: Global IBS Market, Revenues ($bn), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the IBS Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for IBS, 2010 12
Figure 5: Technology Trends Analytic Framework of the IBS Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of IBS, Description, 2010 22
Figure 7: IBS Market Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8: IBS Pipeline by Phase of Clinical Development, 2010 31
Figure 9: Implications for Future Market Competition in the IBS Market, 2010 35
Figure 10: IBS Market Clinical Pipeline by Company, 2010 37
Figure 11: GlobalData Market Forecasting Model, 2010 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *